Rare esophageal tumors

Article written and reviewed by Dr Luca Moretti

Rare esophageal tumors comprise a heterogeneous group of primary neoplasms characterized by low incidence, substantial biological complexity, and major diagnostic and therapeutic challenges. Unlike squamous cell carcinoma and adenocarcinoma, these tumors arise from non-epithelial cell lines or from distinctive histologic compartments of the esophageal wall, including melanocytes, neuroendocrine cells, mesenchymal tissues, and lymphoid cells. Their rarity often makes a multidisciplinary specialist approach and accurate assessment based on advanced endoscopy, extensive pathologic evaluation, and immunophenotyping necessary. The following sections present the principal categories of rare primary esophageal tumors, each with a link to the corresponding detailed monograph.

Primary esophageal melanoma
Primary esophageal melanoma is an extremely rare neoplasm arising from melanocytes located in the basal layer of the esophageal mucosa. It is characterized by marked biological aggressiveness, a rapid tendency toward metastatic dissemination, and a generally unfavorable prognosis. Clinically, it often presents with progressive dysphagia, weight loss, and occult or overt bleeding. Diagnosis is based on histologic and immunohistochemical identification, with expression of specific melanocytic markers. The dedicated monograph discusses its epidemiology, pathogenesis, clinical features, and treatment in detail.

High-grade esophageal neuroendocrine carcinoma
High-grade esophageal neuroendocrine carcinomas are highly aggressive, rapidly growing neoplasms with a pronounced tendency toward early metastasis. They may have large-cell or small-cell morphology and are often diagnosed at an advanced stage. Clinically, they may be associated with nonspecific symptoms or rapidly progressive dysphagia and retrosternal pain. Diagnosis requires histologic confirmation with neuroendocrine markers and assessment of the proliferative index. Treatment is based predominantly on systemic oncologic strategies.

Well-differentiated esophageal neuroendocrine tumors
Well-differentiated esophageal neuroendocrine tumors form a distinct category from high-grade tumors, with slower growth and variable biological behavior. They are often diagnosed incidentally during endoscopy performed for other reasons. Classification is based on histologic grade and proliferative index, which influence prognosis and treatment strategies. Management may include endoscopic, surgical, or systemic approaches according to disease extent.

Primary esophageal sarcomas
Primary esophageal sarcomas arise from mesenchymal tissues of the esophageal wall and include several histologic entities, such as leiomyosarcomas and other rare sarcomas. They frequently present as submucosal masses, with expansile growth and symptoms related to luminal obstruction. Diagnosis requires deep biopsies and immunohistochemical characterization. Treatment is predominantly surgical, often within a multidisciplinary setting.

Primary esophageal lymphomas
Primary esophageal lymphomas are exceptional and result from neoplastic proliferation of mucosa-associated lymphoid tissue. They may present with dysphagia, chest pain, or bleeding, sometimes mimicking other esophageal disorders. Diagnosis is based on endoscopic biopsy with immunophenotypic and molecular assessment. Treatment is generally systemic and depends on the identified lymphoma subtype.

Taken together, rare esophageal tumors represent an area of substantial clinical and scientific complexity, in which correct identification of the histologic subtype and multidisciplinary assessment are decisive for treatment selection and prognosis. In-depth knowledge of these entities helps prevent diagnostic errors, treatment delays, and inappropriate over- or undertreatment, thereby improving overall patient management.

References
1. Voltaggio L et al. Primary malignant melanoma of the esophagus: clinicopathologic and immunohistochemical study. Am J Surg Pathol. 35(6), 2011, 822–830.
2. Bosman FT et al. WHO Classification of Tumours of the Digestive System. IARC Press, Lyon, 2019.
3. Yamaguchi T et al. Neuroendocrine carcinoma of the esophagus: clinicopathological features and treatment outcomes. Dis Esophagus. 27(4), 2014, 350–356.
4. Klimstra DS et al. The pathologic classification of neuroendocrine tumors. Pancreas. 39(6), 2010, 707–712.
5. Miettinen M et al. Mesenchymal tumors of the esophagus. Semin Diagn Pathol. 33(2), 2016, 101–111.
6. Delektorskaya VV et al. Primary sarcomas of the esophagus: clinicopathologic analysis. Virchows Arch. 470(3), 2017, 299–308.
7. Zullo A et al. Primary esophageal lymphoma: clinical and endoscopic features. Endoscopy. 42(8), 2010, 658–663.
8. Ferreri AJM et al. Extranodal lymphomas of the gastrointestinal tract. Best Pract Res Clin Haematol. 25(1), 2012, 119–130.
9. Rice TW et al. Esophageal cancer: staging system and guidelines. J Thorac Oncol. 12(7), 2017, 1050–1068.
10. Ajani JA et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 20(2), 2022, 1–47.